The Peaceful Pill Handbook Analysis

[Santi Dubrova]

Thebook is primarily intended for seniors, people who are seriously ill, and their families and friends. It is also a resource guide for those working in public health and elderly care. The book rates more than a dozen methods of euthanasia according to reliability and peacefulness scales.

Strategies covered by the books include: the use of gases such as nitrogen, poisons such as carbon monoxide, prescription drugs such as insulin and the opiates, and former prescription drugs such as the barbiturates.[2] The book details lawful means of obtaining and administering the drugs, and other peripheral issues such as drug storage, shelf life and disposal. The Swiss assisted suicide services are also covered in detail, as are issues such as the writing of wills, advance directives, and issues of determining decision-making capacity.

One of the more controversial aspects of the book is its coverage of the Internet as a source of drugs. To this end, the authors publish a regular neighbourhood watch that warns about Internet scammers and fraudulent websites.

While the book was initially granted an 18+ rating in Australia, this was overturned on appeal from the Australian Attorney-General. In early 2007, the publication was refused classification (RC) by the Classification Board.[3] In 2009, the Australian government included the handbook website in its internet filtering plan known as the Clean Feed.[4]

In 2008, the Society for Promotion of Community Standards objected to the book's publication. This led to its banning in New Zealand on the grounds that it was an objectionable publication.[5] A short time later, the book was republished in redacted form and is available only if sealed, and an indication of the censorship classification is displayed.[6][7]

Peaceful Pill Handbook 2013 Pdf Torrent ??? ??? Download book is primarily intended for seniors, people who are seriously ill, and their families and friends. It is also a resource guide for those working in public health and elderly care. The book rates more than a dozen methods of euthanasia according to reliability and peacefulness scales.While the book was initially granted an 18+ rating in Australia, this was overturned on appeal from the Australian Attorney-General. In early 2007, the publication was refused classification (RC) by the Classification Board.[2] In 2009, the Australian government included the handbook website in its internet filtering plan known as the Clean Feed.[3]In Australia it is illegal to use a telephone, fax, email or the internet to discuss or research assisted suicide. Downloading the handbook carries a maximum $110,000 fine, but no Australian has been charged.He joined WAVES (now DWDWA) and then Exit International. Through Exit he obtained the Peaceful Pill Handbook. He studied this and decided that his best option for a peaceful death was Nembutal. Nembutal can be bought legally in many countries but not in Australia. Through Exit he obtained online information about Nembutal suppliers in China. He contacted several of these and found one that would supply him with 10g of Nembutal powder for US $250. He ordered and paid for the drug online.He sat in his favourite chair looking out over our bush block with a little table in front of him with a 50ml glass of water, the Nembutal powder and a glass of the port his son had bought him for Xmas. He mixed the powder into the water, drank it down and drank the glass of port to cover the taste of the drug and help its effectiveness. I sat beside him and held his hand as he lay back in the chair and went to sleep. Then his breathing slowed down and stopped and after a short while a little pulse by his mouth stopped. His death was peaceful and dignified. He was in the house that he had helped to build, looking out over the block that he loved, with me beside him. 28789f854f

This document has been prepared by the Cannabis Legalization and Regulation Branch at Health Canada to provide information on the use of cannabis (marihuana) and cannabinoids for medical purposes. This document is a summary of peer-reviewed literature and international reviews concerning potential therapeutic uses and harmful effects of cannabis and cannabinoids. It is not meant to be comprehensive and should be used as a complement to other reliable sources of information. This document is not a systematic review or meta-analysis of the literature and has not rigorously evaluated the quality and weight of the available evidence nor has it graded the level of evidence. Despite the similarity of format, it is not a Drug Product Monograph, which is a document which would be required if the product were to receive a Notice of Compliance authorizing its sale in Canada.

Cannabis is not an approved therapeutic product, unless a specific cannabis product has been issued a drug identification number (DIN) and a notice of compliance (NOC). The provision of this information should not be interpreted as an endorsement of the use of this product, or cannabis and cannabinoids generally, by Health Canada.

Reporting adverse reactions associated with the use of cannabis and cannabis products is important in gathering much needed information about the potential harms of cannabis and cannabis products for medical purposes. When reporting adverse reactions, please provide as much complete information as possible including the name of the licensed producer, the product brand name, the strain name, and the lot number of the product used in addition to all other information available for input in the adverse reaction reporting form. Providing Health Canada with as much complete information as possible about the adverse reaction will help Health Canada with any follow-ups or actions that may be required.

Any suspected adverse reactions associated with the use of cannabis and cannabis products (dried, oils, fresh) for medical purposes should be reported to the Canada Vigilance Program by one of the following three ways:

Acknowledgements:

Health Canada would like to acknowledge and thank the following individuals for their comments and suggestions with regard to the content in this information document:

The following bullet-point statements are meant to summarize the content found within sections 4.0 (Potential Therapeutic Uses) and 7.0 (Adverse Effects) and their respective subsections. The bullet-point statements can also be found in their respective sections and sub-sections in the body of the document itself. Note: most, but not all, clinical studies of cannabis (experimental or therapeutic) have been conducted with dried cannabis containing more THC than CBD and typically, but not always, with lower-potency THC (Important Note: For the sake of completeness and for contextual purposes, the content in the following document includes information on dried cannabis and other cannabis-based products as well as selected cannabinoids. However, cannabis products and cannabinoids should not be considered equivalent even though the information on such products is presented together within the text. Cannabis and cannabis products are highly complex materials with hundreds of chemical constituents whereas cannabinoids are typically single molecules. Drawing direct comparisons between cannabis products and cannabinoids must necessarily take into account differences in the route of administration, dosage, individual pharmacological components and their potential interactions, and the different pharmacokinetic and pharmacodynamic properties of these different substances.

The endocannabinoid system (ECS) (Figure 1) is an ancient, evolutionarily conserved, and ubiquitous lipid signaling system found in all vertebrates, and which appears to have important regulatory functions throughout the human bodyReference 1. The ECS has been implicated in a very broad number of physiological as well as pathophysiological processes including nervous system development, immune function, inflammation, appetite, metabolism and energy, homeostasis, cardiovascular function, digestion, bone development and bone density, synaptic plasticity and learning, pain, reproduction, psychiatric disease, psychomotor behaviour, memory, wake/sleep cycles, and the regulation of stress and emotional state/moodReference 2-Reference 4. Furthermore, there is strong evidence that dysregulation of the ECS contributes to many human diseases including pain, inflammation, psychiatric disorders and neurodegenerative diseasesReference 5.

The ECS consists mainly of: the cannabinoid 1 and 2 (CB1 and CB2) receptors; the cannabinoid receptor ligands N-arachidonoylethanolamine ("anandamide") and 2-arachidonoylglycerol (2-AG); the endocannabinoid-synthesizing enzymes N-acyltransferase, phospholipase D, phospholipase C-β and diacylglycerol-lipase (DAGL); and the endocannabinoid-degrading enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) (Figure 1)Reference 2. Anandamide and 2-AG are considered the primary endogenous activators of cannabinoid signaling, but other endogenous molecules, which exert "cannabinoid-like" effects, have also been described. These other molecules include 2-arachidonoylglycerol ether (noladin ether), N -arachidonoyl-dopamine, virodhamine, N -homo-γ-linolenoylethanolamine and N-docosatetraenoylethanolamineReference 2Reference 6-Reference 9. Other molecules such as palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) do not appear to bind to cannabinoid receptors but rather to a specific isozyme belonging to a class of nuclear receptors/transcription factors known as peroxisome proliferator-activated receptors (PPARs)Reference 9. These fatty acyl ethanolamides may, however, potentiate the effect of anandamide by competitive inhibition of FAAH, and/or through direct allosteric effects on other receptors such as the transient receptor potential vanilloid (TRPV1) channelReference 10. This type of effect has been generally referred to as the so-called "entourage effect"Reference 10Reference 11. The term "entourage effect" is also used in the context of the interactions between phytocannabinoids and terpenes in a physiological system (see Section 1.1.2).

3a8082e126